NASDAQ:KYMR Kymera Therapeutics Q3 2026 Earnings Report $105.98 -3.87 (-3.52%) Closing price 10/6/2026 04:00 PM EasternExtended Trading$106.06 +0.08 (+0.08%) As of 05:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Kymera Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$1.26Beat/MissN/AOne Year Ago EPSN/AKymera Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$3.10 millionBeat/MissN/AYoY Revenue GrowthN/AKymera Therapeutics Announcement DetailsQuarterQ3 2026Date11/3/2026TimeBefore Market OpensConference Call DateTuesday, November 3, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Kymera Therapeutics Earnings HeadlinesKymera Therapeutics (NASDAQ:KYMR) Stock: Insider Nello Mainolfi Sells 30,000 SharesOctober 3, 2026 | americanbankingnews.comKuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law FirmSeptember 30, 2026 | prnewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 7 at 1:00 AM | Banyan Hill Publishing (Ad)Kymera Therapeutics en foro Stifel: ruta acelerada para su fármaco líderSeptember 24, 2026 | mx.investing.comKymera Therapeutics al forum Stifel: percorso accelerato per il farmaco principaleSeptember 24, 2026 | it.investing.comPiper Sandler维持Kymera Therapeutics股票"增持"评级，目标价$140September 23, 2026 | cn.investing.comSee More Kymera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kymera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kymera Therapeutics and other key companies, straight to your email. Email Address About Kymera TherapeuticsKymera Therapeutics (NASDAQ:KYMR) is a clinical-stage biotechnology company focused on developing medicines that selectively remove disease-causing proteins from cells. The company uses its targeted protein degradation platform, including molecular glue degraders, to address proteins that may be difficult to inhibit with conventional small-molecule drugs. Kymera’s research and development activities center on immune-inflammatory diseases and cancer. Its pipeline has included investigational degraders designed to target proteins such as interleukin-1 receptor-associated kinase 4 (IRAK4) and signal transducer and activator of transcription 6 (STAT6), with the goal of treating conditions involving abnormal immune signaling. The company does not have a marketed product and remains focused on advancing its candidates through clinical development. Founded in 2016 and headquartered in Watertown, Massachusetts, Kymera conducts research and clinical development primarily in the United States while working with international collaborators and partners. The company was co-founded by Nello Mainolfi, Ph.D., who has served as its president and chief executive officer and remains associated with the company’s scientific and corporate leadership.View Kymera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02 Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
